News

Filter

1 to 9 of 33 results

AstraZeneca to showcase inflammation/ autoimmunity pipeline at ACR

AstraZeneca to showcase inflammation/ autoimmunity pipeline at ACR

11-11-2014

Anglo-Swedish pharma major AstraZeneca, with its global biologics R&D subsidiary MedImmune, will present…

anifrolumabAnti-Arthritics/RheumaticsAstraZenecaBiotechnologybrodalumabInflammatory diseaseslesinuradMavrilimumabMedImmuneResearchSifalimumabUSA

Timing of AstraZeneca’s positive pipeline announcement “pertinent” in wake of takeover battle with Pfizer, say GlobalData analysts

21-05-2014

Anglo-Swedish drug major AstraZeneca may have more ammunition to deliver on promises made to investors…

Anti-Arthritics/RheumaticsAstraZenecaBiotechnologyImmunologicalsMavrilimumabMedImmuneResearchSifalimumab

Positive top-line results for MedImmune RA and lupus treatments

Positive top-line results for MedImmune RA and lupus treatments

13-05-2014

Anglo-Swedish drug major AstraZeneca has announced that two key molecules in its global biologics R&D…

Anti-Arthritics/RheumaticsAstraZenecaBahija JallalHealthHealth Medical PharmaMajorMedicineMedImmunePharmaceuticalResearchUK

AstraZeneca lesinurad meets Ph III goal in gout patients

AstraZeneca lesinurad meets Ph III goal in gout patients

16-12-2013

Anglo-Swedish drug major AstraZeneca has released positive top-line results from LIGHT, a Phase III…

Anti-Arthritics/RheumaticsAstraZenecaInflammatory diseaseslesinuradPharmaceuticalResearch

Horizon Pharma gets US rights for Vimovo from AstraZeneca

Horizon Pharma gets US rights for Vimovo from AstraZeneca

19-11-2013

USA-based Horizon Pharma has entered into an agreement to acquire from Anglo-Swedish drug major AstraZeneca…

Anti-Arthritics/RheumaticsAstraZenecaHorizon PharmaLicensingNorth AmericaPharmaceuticalPozenVimovo

Arthritis drug disappointment: will fostamatinib's failure force pharma back to the drawing board?

10-06-2013

Recent news of fostamatinib's latest failure to meet clinical endpoints marks yet another blow to an…

Anti-Arthritics/RheumaticsAstraZenecaBiotechnologyEli LillyfostamatinibPfizerPharmaceuticalRegulationResearchRigel PharmaceuticalstabalumabXeljanz

AstraZeneca returns fostamatinib program rights to Rigel

04-06-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US partner Rigel Pharmaceuticals (Nasdaq: RIGL) today…

Anti-Arthritics/RheumaticsAstraZenecafostamatinibLicensingPharmaceuticalResearchRigel Pharmaceuticals

Research briefs: Lilly's Forteo; Genmab/GSK's Arzerra; AstraZeneca's Symbicort

30-05-2013

US drug major Eli Lilly (NYSE: LLY) has reported new data demonstrating that Forteo (teriparatide) significantly…

Anti-Arthritics/RheumaticsArzerraAstraZenecaEli LillyForteoGenmabGlaxoSmithKlineOncologyPharmaceuticalResearchRespiratory and PulmonarySymbicort

1 to 9 of 33 results

Back to top